Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Stock Now Rated “Buy” by Wall Street Analysts

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has been assigned an average recommendation of “Buy” from the fourteen ratings firms that are presently covering the stock, MarketBeat.com reports. Twelve analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $43.90.

AAPG has been the subject of a number of research reports. Citizens Jmp began coverage on Ascentage Pharma Group International in a research note on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 price target for the company. JPMorgan Chase & Co. cut their price objective on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a report on Thursday, October 8th. BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. William Blair assumed coverage on Ascentage Pharma Group International in a report on Friday, October 16th. They issued an “outperform” rating for the company. Finally, Citigroup initiated coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, October 14th. They set a “buy” rating and a $46.00 price target for the company.

Ascentage Pharma Group International Stock Down 8.7%

Shares of NASDAQ AAPG opened at $14.92 on Friday. The stock’s fifty day moving average price is $16.22 and its two-hundred day moving average price is $18.76. Ascentage Pharma Group International has a one year low of $14.45 and a one year high of $35.46. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million for the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International will post -2.43 earnings per share for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.